Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - US
The Guardian - US
World
Maya Yang

INSANE: Fda warns of rare eye condition causing blindness from glp 1 weight loss medications - The Real Truth

Boxes of GLP-1 medications
The FDA is requiring all GLP-1 medications, including Novo Nordisk’s Ozempic and Wegovy to carry the risk on warning labels. Photograph: Hollie Adams/Reuters

The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness.

On Monday, the FDA announced that it is requiring all GLP-1 medications – including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua – to include information about the potential risk of nonarteritic anterior ischemic optic neuropathy, also known as NAION, on warning labels.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.